luspatercept-aamt 25 MG Injection
- RxCUI
- 2262906
- RxNorm name
- luspatercept-aamt 25 MG Injection
- Display name
- luspatercept-aamt 25 MG Injection
- Full name
- luspatercept-aamt 25 MG Injection
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:06
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761136 | Reblozyl | luspatercept-aamt | 351(a) | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Reblozyl | LUSPATERCEPT | Celgene Corporation | 82f4d266-3f52-41eb-86ba-0abf3cf468e8 | 2026-02-27 | Warnings, Adverse reactions | 2262906 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 82f4d266-3f52-41eb-86ba-0abf3cf468e8 | luspatercept-aamt 25 MG Injection | SCD | 20 | These highlights do not include all the information needed to use REBLOZYL safely and effectively. See full prescribing information for REBLOZYL. REBLOZYL ® (luspatercept-aamt) for injection, for subcutaneous use Initial U.S. Approval: 2019 | 20260227 |
| 82f4d266-3f52-41eb-86ba-0abf3cf468e8 | luspatercept-aamt 25 MG Injection | PSN | 20 | These highlights do not include all the information needed to use REBLOZYL safely and effectively. See full prescribing information for REBLOZYL. REBLOZYL ® (luspatercept-aamt) for injection, for subcutaneous use Initial U.S. Approval: 2019 | 20260227 |